Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective
暂无分享,去创建一个
Thanyada Rungrotmongkol | Nadtanet Nunthaboot | Thitiya Boonma | Bodee Nutho | T. Rungrotmongkol | Nadtanet Nunthaboot | B. Nutho | Thitiya Boonma
[1] Susanne Nyström,et al. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. , 2010, Angewandte Chemie.
[2] Gamal Esmat,et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.
[3] Tingjun Hou,et al. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..
[4] P. Kollman,et al. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .
[5] Weiwei Xue,et al. Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis , 2014, J. Chem. Inf. Model..
[6] Nopporn Kaiyawet,et al. Effect of Halogen Substitutions on dUMP to Stability of Thymidylate Synthase/dUMP/mTHF Ternary Complex Using Molecular Dynamics Simulation , 2013, J. Chem. Inf. Model..
[7] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[8] Irwin D Kuntz,et al. Free energy calculations for theophylline binding to an RNA aptamer: Comparison of MM-PBSA and thermodynamic integration methods. , 2003, Biopolymers.
[9] A. De Luca,et al. Treatment of HCV infection with the novel NS3/4A protease inhibitors. , 2014, Current opinion in pharmacology.
[10] Rebecca T. Ruck,et al. Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor. , 2016, ACS medicinal chemistry letters.
[11] Hong Cao,et al. The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors , 2012, PLoS pathogens.
[12] Wei Zhang,et al. Prediction of binding for a kind of non-peptic HCV NS3 serine protease inhibitors from plants by molecular docking and MM-PBSA method. , 2007, Bioorganic & medicinal chemistry.
[13] S. Locarnini,et al. Hepatitis C virus resistance to protease inhibitors. , 2011, Journal of hepatology.
[14] M. Rudd,et al. Hepatitis C virus NS3/4a protease inhibitors. , 2016, Current opinion in pharmacology.
[15] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[16] C. Schiffer,et al. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors , 2019, Critical reviews in biochemistry and molecular biology.
[17] Huanxiang Liu,et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. , 2012, Antiviral research.
[18] P. Kollman,et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.
[19] C. Schiffer,et al. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. , 2016, Journal of the American Chemical Society.
[20] M Karplus,et al. Zinc binding in proteins and solution: A simple but accurate nonbonded representation , 1995, Proteins.
[21] Xiaojie Xu,et al. Recent Advances in Free Energy Calculations with a Combination of Molecular Mechanics and Continuum Models , 2006 .
[22] C. Schiffer,et al. Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease , 2014, ACS chemical biology.
[23] Bin Wang,et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. , 2014, Journal of medicinal chemistry.
[24] Jing Wei,et al. Molecular dynamics study on drug resistance mechanism of HCV NS3/4A protease inhibitor: BI201335 , 2015 .
[25] S. Jamal,et al. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease. , 2015, Gene.
[26] T. Hassanein,et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. , 2017, Journal of hepatology.
[27] A. Molla,et al. In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450 , 2014, Antimicrobial Agents and Chemotherapy.
[28] Conrad C. Huang,et al. UCSF Chimera, MODELLER, and IMP: an integrated modeling system. , 2012, Journal of structural biology.
[29] T. Pilot‐Matias,et al. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. , 2019, Future microbiology.
[30] A. Warshel,et al. Exploring the Drug Resistance of HCV Protease. , 2017, The journal of physical chemistry. B.
[31] Huanxiang Liu,et al. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. , 2012, Molecular bioSystems.
[32] O. Yokosuka,et al. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. , 2013, World journal of gastroenterology.
[33] C. Schiffer,et al. Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. , 2018, ACS medicinal chemistry letters.
[34] Wei Huang,et al. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. , 2017, Journal of medicinal chemistry.
[35] M. Manns,et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.
[36] C. Simmerling,et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.
[37] Youyong Li,et al. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations. , 2015, Molecular bioSystems.
[38] T. Rungrotmongkol,et al. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1. , 2012, Journal of molecular graphics & modelling.
[39] K. Sharp,et al. Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .
[40] Thanyada Rungrotmongkol,et al. Molecular Dynamic Behavior and Binding Affinity of Flavonoid Analogues to the Cyclin Dependent Kinase 6/cyclin D Complex , 2012, J. Chem. Inf. Model..
[41] Holger Gohlke,et al. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.
[42] C. Schiffer,et al. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. , 2018, Structure.
[43] J. Lennerstrand,et al. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach , 2016, Interdisciplinary Sciences: Computational Life Sciences.
[44] D. Case,et al. Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.
[45] T. Rungrotmongkol,et al. Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. , 2016, Molecular bioSystems.